Jump to content
Advertisement

IBS News

Showing topics posted by Health Reporter and posted in for the last 365 days.

This stream auto-updates     

  1. Yesterday
  2. School's strict loo roll rules leaves child 'too scared to go to the toilet' WalesOnlineView the full article
  3. RT @FODMAPLife: Join me as I host @KateScarlata_RD for a Facebook Live broadcast, “Constipation Remedies.” Tues., Nov 19 at 1 p.m. EST. Sponsored by @OrgranGF Join us HERE: http://bit.ly/ConstipationRemedy #lowfodmap #fodmap #guthealth #dietitian #digestivehealth #guthealth #constipation https://t.co/y0UigAYf4v (Feed generated with FetchRSS) View the full article
  4. RT @MsKymLang: A thought-provoking article on IBS and stigma by dietitian @KateScarlata_RD https://blog.katescarlata.com/2019/11/13/ibs-stigma/ #IBS (Feed generated with FetchRSS) View the full article
  5. Last week
  6. Related Articles Adherence to the pro-inflammatory diet in relation to prevalence of irritable bowel syndrome. Nutr J. 2019 Nov 11;18(1):72 Authors: Salari-Moghaddam A, Keshteli AH, Esmaillzadeh A, Adibi P Abstract OBJECTIVE: There is no prior study that examined the association between nutrient-based dietary inflammatory index (DII) and odds of Irritable Bowel Syndrome (IBS). We examined the association between DII score and odds of IBS and its severity among Iranian adults. METHODS: In this cross-sectional study, dietary intakes of 3363 Iranian adults were examined using a validated Dish-based 106-item Semi-quantitative Food Frequency Questionnaire (DS-FFQ). DII was calculated based on dietary intakes derived from DS-FFQ. IBS was assessed using a modified Persian version of Rome III questionnaire. RESULTS: After adjustment for potential confounders, we found that participants in the highest quintile of DII score had greater chance for IBS compared with those in the lowest quintile (OR: 1.36; 95% CI: 1.03-1.80). By gender, we found a significant association between DII score and IBS among women (OR: 1.41; 95% CI: 1.00-2.00). By BMI status, overweight or obese (BMI ≥ 25 kg/m2) individuals in top quintile of DII score had greater odds for IBS than those in the bottom quintile (OR: 1.64; 95% CI: 1.07-2.53). No significant association was observed between a pro-inflammatory diet and severity of IBS symptoms. CONCLUSIONS: Consumption of a pro-inflammatory diet was associated with increased odds of IBS, in particular among women and those with BMI ≥ 25 kg/m2. PMID: 31711479 [PubMed - in process] View the full article
  7. Related Articles Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction, Based on IBS in America Survey. Gastroenterology. 2019 Nov 08;: Authors: Rangan V, Ballou S, Shin A, Camilleri M, Beth Israel Deaconess Medical Center GI Motility Working Group, Lembo A PMID: 31711922 [PubMed - as supplied by publisher] View the full article
  8. Related Articles Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. Gastroenterology. 2019 Nov 08;: Authors: Kamphuis JBJ, Guiard B, Leveque M, Olier M, Jouanin I, Yvon S, Tondereau V, Rivière P, Guéraud F, Chevolleau S, Noguer-Meireles MH, Martin JF, Debrauwer L, Eutamène H, Theodorou V Abstract BACKGROUND AND AIMS: Irritable bowel syndrome (IBS) is characterized by abdominal pain, bloating, and erratic bowel habits. A diet low in fermentable oligo-, di-, mono-saccharides and polyols (FODMAPs) can reduce symptoms of IBS, possibly by reducing microbial fermentation products. We investigated whether ingestion of FODMAPs can induce IBS-like visceral hypersensitivity mediated by fermentation products of intestinal microbes in mice. METHODS: C57Bl/6 mice were gavaged with lactose, with or without the anti-glycation agent pyridoxamine, or saline (controls) daily for 3 weeks. A separate group of mice were fed a diet containing fructo-oligosaccharides, with or without pyridoxamine in drinking water, or a normal chow diet (controls) for 6 weeks. Feces were collected and analyzed by 16S rRNA gene sequencing and bacterial community analyses. Abdominal sensitivity was measured by electromyography and mechanical von Frey filament assays. Colon tissues were collected from some mice and analyzed by histology and immunofluorescence, to quantify mast cells and expression of advanced glycosylation end-product specific receptor (AGER). RESULTS: Mice gavaged with lactose or fed fructo-oligosaccharides had increased abdominal sensitivity compared with controls, associated with increased numbers of mast cells in colon and expression of the receptor for AGER in proximal colon epithelium. These effects were prevented by administration of pyridoxamine. Lactose and/or pyridoxamine did not induce significant alterations in the composition of the fecal microbiota. Mass spectrometric analysis of carbonyl compounds in fecal samples identified signatures associated with mice given lactose or fructo-oligosaccharides vs controls. CONCLUSION: We found that oral administration of lactose or fructo-oligosaccharides to mice increases abdominal sensitivity, associated with increased numbers of mast cells in colon and expression of AGER; these can be prevented with an anti-glycation agent. Lactose and/or pyridoxamine did not produce alterations in fecal microbiota of mice. Our findings indicate that preventing glycation reactions might reduce abdominal pain in patients with IBS with sensitivity to FODMAPs. PMID: 31711923 [PubMed - as supplied by publisher] View the full article
  9. Biofeedback for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2019 Nov 12;2019(11): Authors: Goldenberg JZ, Brignall M, Hamilton M, Beardsley J, Batson RD, Hawrelak J, Lichtenstein B, Johnston BC Abstract BACKGROUND: Irritable bowel syndrome (IBS) is a prevalent condition that currently lacks highly effective therapies for its management. Biofeedback has been proposed as a therapy that may help individuals learn to exert conscious control over sympatho-vagal balance as an indirect method of symptom management. OBJECTIVES: Our primary objective was to assess the efficacy and safety of biofeedback-based interventions for IBS in adults and children. SEARCH METHODS: We searched the Cochrane Inflammatory Bowel Disease (IBD) Group Specialized Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the Allied and Complementary Medicine Database (AMED) from inception to 24 July 2019. We also searched reference lists from published trials, trial registries, device manufacturers, conference proceedings, theses, and dissertations. SELECTION CRITERIA: We judged randomized controlled trials to be eligible for inclusion if they met the Association for Applied Psychophysiology and Biofeedback definition of biofeedback, and if they compared a biofeedback intervention to an active, sham, or no-treatment control for the management of IBS. DATA COLLECTION AND ANALYSIS: Two authors independently screened trials for inclusion, extracted data, and assessed risk of bias. Primary outcomes were IBS global or clinical improvement scores and overall quality of life measures. Secondary outcome measures were adverse events, assessments of stool frequency and consistency, changes in abdominal pain, depression, and anxiety. For dichotomous outcomes, we calculated the risk ratio (RR) and 95% confidence interval (CI). For continuous outcomes, we calculated the mean difference (MD) and 95% CI. We used GRADE criteria to assess the overall certainty of the evidence. MAIN RESULTS: We identified eight randomized trials with a total of 300 adult participants for our analysis. We did not identify any trials in children. Four trials assessed thermal biofeedback. One trial assessed rectosigmoidal biofeedback. Two trials assessed heart rate variability biofeedback. Two trials assessed electrocutaneous biofeedback. Comparators were: no treatment (symptom monitoring group; three studies), attention control (pseudomeditation; two studies), relaxation control (one study), counseling (two studies), hypnotherapy (one study), standard therapy (one study), and sham biofeedback (one study). We judged all trials to have a high or unclear risk of bias. Global/Clinical improvement The clinical benefit of biofeedback plus standard therapy compared to standard therapy alone was uncertain (RR 4.20, 95% CI 1.40 to 12.58; 1 study, 20 participants; very low-certainty evidence). The same study also compared biofeedback plus standard therapy to sham biofeedback plus standard therapy. The clinical benefit in the biofeedback group was uncertain (RR 2.33, 95% CI 1.13 to 4.80; 1 study, 20 participants; very low-certainty evidence). The clinical benefit of heart rate biofeedback compared to hypnotherapy was uncertain when measured with the IBS severity scoring system (IBS-SSS) (MD -58.80, 95% CI -109.11 to -8.49; 1 study, 61 participants; low-certainty evidence). Compared to counseling, the effect of heart rate biofeedback was unclear when measured with a composite symptom reduction score (MD 7.03, 95% CI -51.07 to 65.13; 1 study, 29 participants; low-certainty evidence) and when evaluated for clinical response (50% improvement) (RR 1.09, 95% CI 0.48 to 2.45; 1 study, 29 participants; low-certainty evidence). The clinical benefit of thermal biofeedback used in a multi-component psychological intervention (MCPI) compared to no treatment was uncertain when measured with a composite clinical symptom reduction score (MD 30.34, 95% CI 8.47 to 52.21; 3 studies, 101 participants; very low-certainty evidence), and when evaluated as clinical response (50% improvement) (RR 2.12, 95% CI 1.24 to 3.62; 3 studies, 101 participants; very low-certainty evidence). Compared to attention control, the effects of thermal biofeedback within an MCPI were unclear when measured with a composite clinical symptom reduction score (MD 4.02, 95% CI -21.41 to 29.45; 2 studies, 80 participants; very low-certainty evidence) and when evaluated as clinical response (50% improvement) (RR 1.10, 95% CI 0.72 to 1.69, 2 studies, 80 participants; very low-certainty evidence). Quality of life A single trial used overall quality of life as an outcome measure, and reported that both the biofeedback and cognitive therapy groups improved after treatment. The trial did not note any between-group differences, and did not report any outcome data. Adverse events Only one of the eight trials explicitly reported adverse events. This study reported no adverse events in either the biofeedback or cognitive therapy groups (RD 0.00, 95% CI -0.12 to 0.12; 29 participants; low-certainty evidence). AUTHORS' CONCLUSIONS: There is currently not enough evidence to assess whether biofeedback interventions are effective for controlling symptoms of IBS. Given the positive results reported in small trials to date, biofeedback deserves further study in people with IBS. Future research should include active control groups that use high provider-participant interaction, in an attempt to balance non-specific effects of interventions between groups, and report both commonly used outcome measures (e.g. IBS-SSS) and historical outcome measures (e.g. the composite primary symptom reduction (CPSR) score) to allow for meta-analysis with previous studies. Future studies should be explicit in their reporting of adverse events. PMID: 31713856 [PubMed - in process] View the full article
  10. Identification of Three Antimicrobials Activating Serotonin Receptor 4 in Colon Cells. ACS Synth Biol. 2019 Nov 12;: Authors: Yasi EA, Allen AA, Sugianto W, Peralta-Yahya P Abstract The serotonin receptor 4b (5-HTR4b) is expressed throughout the gastrointestinal tract, and its agonists are used in the treatment of irritable bowel syndrome with constipation (IBS-C). Today, there are no rapid assays for the identification of 5-HTR4b agonists. Here, we developed a luciferase-based 5-HTR4b assay capable of assessing one compound per second with a 38-fold dynamic range and nM limit of detection for serotonin. We used the assay to screen more than 1000 natural products and anti-infection agents and identified five new 5-HTR4b ligands: hordenine, halofuginone, proflavine, ethacridine, and revaprazan. We demonstrate that hordenine (antibiofilm), halofuginone (antiparasitic), and revaprazan (gastric acid reducer) activate 5-HTR4b in human colon epithelial cells, leading to increased cell motility or wound healing. The 5-HTR4b assay can be used to screen larger pharmaceutical libraries to identify novel treatments for IBS-C. This work shows that antimicrobials interact not only with the gut microbiota, but also with the human host. PMID: 31714751 [PubMed - as supplied by publisher] View the full article
  11. Stress and the brain-gut axis in functional and chronic-inflammatory gastrointestinal diseases: A transdisciplinary challenge. Psychoneuroendocrinology. 2019 Nov 02;111:104501 Authors: Labanski A, Langhorst J, Engler H, Elsenbruch S Abstract The broad role of stress in the brain-gut axis is widely acknowledged, with implications for multiple prevalent health conditions that are characterized by chronic gastrointestinal symptoms. These include the functional gastrointestinal disorders (FGID), such as irritable bowel syndrome and functional dyspepsia, as well as inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease. Although the afferent and efferent pathways linking the gut and the brain are modulated by stress, the fields of neurogastroenterology and psychoneuroendocrinology (PNE)/ psychoneuroimmunology (PNI) remain only loosely connected. We aim to contribute to bringing these fields closer together by drawing attention to a fascinating, evolving research area, targeting an audience with a strong interest in the role of stress in health and disease. To this end, this review introduces the concept of the brain-gut axis and its major pathways, and provides a brief introduction to epidemiological and clinical aspects of FGIDs and IBD. From an interdisciplinary PNE/PNI perspective, we then detail current knowledge regarding the role of chronic and acute stress in the pathophysiology of FGID and IBD. We provide an overview of evidence regarding non-pharmacological treatment approaches that target central or peripheral stress mechanisms, and conclude with future directions, particularly those arising from recent advances in the neurosciences and discoveries surrounding the gut microbiota. PMID: 31715444 [PubMed - as supplied by publisher] View the full article
  12. Gosport mum shares how bullies caused her IBS in the hope of preventing others being picked on Portsmouth NewsView the full article
  13. Bold Health Partners with the University of Pennsylvania for Clinical Trial of Its Zemedy IBS App PR.comView the full article
  14. RT @ea_haller: Reminder: Join me tomorrow! Excited to be discussing all things diet and IBD & answering all your questions LIVE: @CrohnsColitisFn Nov 13 at 5:00pm Join http://facebook.com/ccfafb (Feed generated with FetchRSS) View the full article
  15. RT @LaurenCornellRD: Many #foods can cause #foodborneillness if they are kept long past their prime. Be sure to check out some general guidelines for how long to store different food types from @foodsafetygov here: https://bit.ly/34OBZSk #HowToTuesday #foodsafety (Feed generated with FetchRSS) View the full article
  16. VIDEO: Human milk oligosaccharides effective in IBS HealioView the full article
  17. Stress and constipation: What is the link? Medical News TodayView the full article
  18. RT @RomeGastroPsych: Read this thread of a girl coming into the ER with persistent vomiting but normal tests. We should invite @raw_em_md to become an honorary member of our Psychogastro family. Well done! https://twitter.com/raw_em_md/status/1192310127409283072 (Feed generated with FetchRSS) View the full article
  19. Did you know Japanese pumpkin, like many other veggies, goes by different names depending on which part of the world you call home? Also, it's completely #FODMAP free! 😍😍 This nutritious vegetable is super versatile and a great source of beta carotene, fibre and vitamins C & E (Feed generated with FetchRSS) View the full article
  20. Related Articles The Gluten-Free Diet: Use in Digestive Disease Management. Curr Treat Options Gastroenterol. 2019 Nov 09;: Authors: Newberry C Abstract PURPOSE OF REVIEW: Gluten is a commonly ingested polymeric protein found in wheat, barley, and rye that has gained recent notoriety because of its relationship to disease and health. Avoidance of gluten is appropriate in patients with a diagnosed gluten-related disorder and may have treatment implications in other diseases of the digestive tract. This review highlights current knowledge of gluten related disorders and the use of a gluten-free diet in gastrointestinal disease management. RECENT FINDINGS: Gluten-free diets should be used in patients with a diagnosed gluten-related disorder including celiac disease, non-celiac gluten sensitivity, and wheat-sensitive eosinophilic esophagitis. Use of this diet in management of other digestive conditions including gastroesophageal reflux disease, irritable bowel syndrome, and inflammatory bowel disease is controversial and not currently supported by the literature. This review provides a framework for classifying gluten-related disorders in terms of pathogenesis, understanding the literature that supports dietary avoidance in modulation of gastrointestinal disease, and identifies limitations of dietary restriction in patients. PMID: 31705373 [PubMed - as supplied by publisher] View the full article
  21. Related Articles Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Adv Ther. 2019 Nov 09;: Authors: Brenner DM, Sayuk GS Abstract Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by abdominal pain and alterations in stool form and/or frequency, leading to reduced quality of life. Pharmacologic agents currently approved by the US Food and Drug Administration for treatment of IBS with diarrhea (IBS-D) in adults are the nonsystemic antibiotic rifaximin, the mixed µ- and κ-opioid receptor agonist/δ-opioid antagonist eluxadoline, and the selective serotonin 5-HT3 antagonist alosetron (the last of which is indicated only in women with severe IBS-D refractory to conventional therapy). Both eluxadoline and alosetron are administered as chronic daily therapies; rifaximin is given as a 2-week course of treatment with repeat courses administered as needed for symptom recurrence. Presumed mechanisms of action of rifaximin include modulation of the gut microbiota, anti-inflammatory activity, normalization of visceral hypersensitivity, and reduction in intestinal permeability. Eluxadoline targets opioid receptors in the gastrointestinal (GI) tract, resulting in decreased GI motility, fluid secretion, and visceral pain perception. Alosetron antagonizes serotonergic afferent neural signals and also slows GI motility. The efficacy and safety of these agents have been investigated in several rigorous clinical trials, and it has been demonstrated that they improve global and individual IBS symptoms. This review highlights the pivotal efficacy and safety data of the three pharmacologic agents currently indicated in the USA for the management of IBS-D in adults.Funding: Salix Pharmaceuticals. PMID: 31707713 [PubMed - as supplied by publisher] View the full article
  22. We know that #IBS can be tricky to understand & even harder to explain to others, so we put together this handy video all about the #FODMAP diet & why it works for people with IBS - Watch here: https://www.youtube.com/watch?v=stdYoA4G9Dg (Feed generated with FetchRSS) View the full article
  23. 6 “Healthy” Habits That Mess With Your Gut BustleView the full article
  24. THREE DAYS TO GO! 🤩Don't miss out on this amazing offer! Sign up for the Monash #FODMAP Online Course with a friend & BOTH RECEIVE 25% off. Complete this short form: https://bit.ly/36kE5uW and our team will then be in touch with your 25% off discount vouchers within 7 days! (Feed generated with FetchRSS) View the full article
  25. Following a #FODMAP diet in India - a nice article summarising how to - http://ow.ly/UsB650x4k3Y (Feed generated with FetchRSS) View the full article
  26. Related Articles Re: A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome. J Clin Med. 2019 Nov 06;8(11): Authors: Appleton L, Day AS Abstract We read with interest the article by Ng et al [...]. PMID: 31698718 [PubMed] View the full article
  27. Related Articles New insights into irritable bowel syndrome: from pathophysiology to treatment. Ann Gastroenterol. 2019 Nov-Dec;32(6):554-564 Authors: Hadjivasilis A, Tsioutis C, Michalinos A, Ntourakis D, Christodoulou DK, Agouridis AP Abstract Irritable bowel syndrome (IBS) is the most common reason to visit a gastroenterologist. IBS was believed to be a functional disease, but many possible pathophysiologic mechanisms can now explain the symptoms. IBS patients are classified into subtypes according to their predominant bowel habit, based on the Rome IV criteria. These include diarrhea-predominant and constipation-predominant IBS, as well as the mixed type, a combination of the two. Usually, IBS treatment is based on the predominant symptoms, with many options for each subtype. A new promising treatment option, fecal microbiota transplantation, seems to have beneficial effects on IBS. However, treating the pathophysiological causative agent responsible for the symptoms is an emerging approach. Therefore, before the appropriate therapeutic option is chosen for treating IBS, a clinical evaluation of its pathophysiology should be performed. PMID: 31700231 [PubMed] View the full article
  1. Load more activity
Advertisement


×
×
  • Create New...